Trippy research: Chemically-induced synesthesia
Article Jul 07, 2015
In April 1943, scientist Albert Hoffman ingested 250 micrograms of a substance he had synthesized five years prior. Less than an hour later, he “perceived an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.”1
Hoffman had discovered lysergic acid diethylamide, a psychedelic drug commonly known as LSD. He had experienced the world’s first acid trip.
Psychedelic drugs like LSD are often associated with experiences that can only be described as synesthesia—the rare neurological phenomenon in which a stimulus produces a second concurrent, involuntary experience—although scientists are still unsure if chemically-induced synesthesia is a genuine synesthetic experience.
The majority of studies on the topic have focused on congenital synesthesia. To date, there have only been four direct studies on chemically-induced synesthesia which were conducted between 1934 and 1966. Indirect studies picked up again in the early 1990s with the work of neurologist Richard Cytowic.
Direct studies suggest it’s possible to chemically-induce synesthesia
In 1934, research conducted by E.L. Kelly and published in the Journal of Experimental Psychology tested auditory-visual synesthesia using five non-synesthetes who first spent seven-weeks being presented with eight different tone-color pairs 1000 to 2000 times. The subjects demonstrated no evidence of developing synesthesia after this initial testing phase. When they consumed 15g of peyote cactus (estimated to contain between 0.15 and 1.2g of the psychoactive stimulant mescaline), four of the participants perceived colorful visual imagery and experienced haptic-visual, kinesthetic-visual, and algesic-color synesthesia. However, the researchers suggested that consumption of mescaline did not enhance trained associations and they observed no evidence of spontaneous auditory-visual synesthesia.2
A second study conducted in 1955 by Simpson and McKeller in the Journal of Mental Science involved two congenital synesthetes (auditory-visual and multiple types). The researchers themselves acted as non-synesthete controls. On separate occasions, subjects were given four mescaline doses (between 0.3 and 0.5g) and were then presented with various stimuli (i.e. visual, auditory, tactile, etc.). Subjects reported experiencing several distinct types of synesthesia, including auditory-visual, kinesthetic-visual, tactile-visual, olfactory-visual, and algesic-visual. Synesthetes and non-synesthetes were equally prone to developing new inducer-concurrent associations. In addition, one of the congenital synesthetes reported enhancements of his regular associations. Once again, the researchers concluded that mescaline seemed to be able to trigger synesthesia among non-synesthetes, but they also suggested that it could enhance the phenomenon in congenital synesthetes.3
A third blind study conducted in 1963 by Hartman and Hollister in Psychopharmacologia compared the effects of mescaline, LSD, and psilocybin (the psychedelic compound found in certain mushrooms). Eighteen participants were given each substance a week apart and were subjected to 16 sonic tones before and after drug administration. Under the influence of LSD and mescaline, but not psilocybin, participants reported significantly more auditory-visual associations compared to baseline levels. Less than 50% of participants experienced auditorily-induced synesthesia under the influence of the drugs.4
The last direct study, conducted in 1966 by Masters and Houston in The Varieties of Psychedelic Experience, was extremely informal. In it, participants were interviewed after consuming psychedelic drugs. The study covered 206 drug sessions and involved a total of 214 subjects.2 The researchers reported successfully inducing auditory-visual and auditory-gustatory synesthesia with LSD, but no other details were provided in their report.5
Possible mechanisms for chemically-induced synesthesia
Because the genetic mechanisms underlying congenital synesthesia are still not well understood and chemically-induced studies are so scarce, scientists are unsure if mechanisms influencing chemically-induced synesthetic episodes are—or are similar to—genuine synesthetic experiences.
In congenital synesthesia, very little systematic quantitative research has investigated the neurochemical factors involved. In mechanisms that propose the phenomenon is promoted by disinhibition, y-aminobutyric acid (GABA) plays a role in the disruption of inhibitory activity.2,6 In 2008, scientists Brang and Ramachandran suggested serotonin (5-hydroxytryptophan) may also play a role.2,7
According to scientist Christopher Sinke from the University of Hannover, hallucinogens appear to inhibit serotonergic neuron transduction.8 The majority of hallucinogens affect activity in two areas: the locus coeruleus and pyramidal cells in the cortex. Because serotonin is primarily an inhibitory neurotransmitter, when its activity is decreased due to drug intake, the activity of the next neuron in the chain increases when it is no longer inhibited. This mechanism would be similar to the disinhibited feedback models of genuine synesthesia.
Crucial differences between congenital and chemically-induced synesthesia
While any two or more combinations of inducer-concurrent experiences are possible, in congenital synesthesia the grapheme-colour association is the most common type. Meanwhile, auditory-visual synesthesia is the most common form noted in chemically-induced cases (approximately 23%). Additionally, visual concurrents are more complex in these cases than in congenital cases. Genuine synesthesia is characterized by consistency and automaticity. Currently, there is still no clear evidence that chemically-induced synesthesia is consistent or automatic.
The limitations of scarce research
It is critical to keep in mind when analyzing the existing chemically-induced research that study participants may have been biased to expect synesthesia under the influence of psychedelics and that the drugs increased participant suggestibility. Additionally, as in Albert Hoffman’s initial experience with LSD in 1943, most studies relied on subjects to self-report their experiences rather than using more consistent, objective methods to screen or measure participants.
While the studies discussed here suggest that it is possible to induce synesthesia using psychedelics, a systematic review conducted in 2013 by the University of Greenwich and Oxford recommends more rigorous examination of the subject including placebo-controlled and double blind investigations.2 Promisingly, we have taken steps in this direction with new research attempting to elucidate the mechanisms that may activate chemically-induced synesthesia through more controlled studies.9
- 1. "Hallucinogenic Effects of LSD Discovered." History.com. A&E Television Networks, n.d. Web. 18 June 2015.
- 2. Luke D, Terhune D (2013) The induction of synaesthesia with chemical agents: a systematic review. Frontiers in Psychology 4:753. doi: 10.3389/fpsyg.2013.00753
- 3. Simpson L, McKellar P (1955) Types of synaesthesia. J. Ment. Sci. 101(422):141–147.
- 4. Hartman AM, Hollister LE (1963) Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia 4(6):441-451. doi: 10.1007/BF00403349
- 5. Masters REL, Houston J (1966) The Varieties of Psychedelic Experience. London: Turnstone.
- 6. Hubbard EM, Brang D, Ramachandran VS (2011) The cross-activation theory at 10. J. Neuropsychol. 5(2):152-177. doi: 10.1111/j.1748-6653.2011.02014.x
- 7. Brang D, Ramachandran VS (2008) Psychopharmacology of synesthesia: the role of seroton in S2a receptor activation. Med. Hypotheses 70(4):903-904. doi: 10.1016/j.mehy.2007.09.007
- 8. Passie T et al. (2012) Genuine and drug-induced synesthesia: A comparison. Consciousness and Cognition 21(3):1419-1434. doi: 10.1016/j.concog.2012.03.009
- 9. Brogaard B, Gatzia E (2015) Psilocybin, LSD, Mescaline and Drug-Induced Synesthesia. Neuropathology of Drug Addictions and Substance Misuse. (In press)
The reproducibility crisis is holding back science. London-based Labstep, a start-up out of Oxford University, think that their tool can help make science more open and reproducible. That claim has now been given some concrete evidence with the announcement that the research contingent of the MRC Unit The Gambia at LSHTM will be trialling Labstep across their Banjul-based facility.READ MORE
Researchers have identified a mechanism by which brain-derived neurotrophic factor (BDNF) can suppress GABAergic transmission in hippocampus. In this article, Dr. Rajamani Selvam explains how he and his team achieved these results, and their potential impact on the treatment of neurological disease.READ MORE